electroCore, Inc. (NASDAQ:ECOR – Free Report) – Equities researchers at HC Wainwright lowered their Q1 2025 earnings per share estimates for electroCore in a research report issued on Thursday, March 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.59) per share for the quarter, down from their prior estimate of ($0.26). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for electroCore’s Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.70) EPS, FY2026 earnings at $0.45 EPS and FY2027 earnings at $1.33 EPS.
Separately, LADENBURG THALM/SH SH decreased their price objective on electroCore from $28.00 to $26.00 and set a “buy” rating for the company in a report on Thursday.
electroCore Stock Down 10.4 %
NASDAQ ECOR opened at $8.56 on Monday. The company has a market cap of $56.98 million, a price-to-earnings ratio of -4.68 and a beta of 0.24. electroCore has a 52 week low of $5.32 and a 52 week high of $19.49. The business has a 50 day moving average price of $15.84 and a 200-day moving average price of $12.35.
Institutional Investors Weigh In On electroCore
Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in shares of electroCore by 31,250.0% during the fourth quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company’s stock valued at $61,000 after acquiring an additional 3,750 shares in the last quarter. DnB Asset Management AS bought a new stake in electroCore during the fourth quarter worth $180,000. NewEdge Advisors LLC purchased a new stake in electroCore in the 4th quarter valued at $274,000. Jane Street Group LLC purchased a new stake in electroCore in the 4th quarter valued at $278,000. Finally, Marshall Wace LLP purchased a new stake in electroCore in the 4th quarter valued at $438,000. Institutional investors own 26.74% of the company’s stock.
About electroCore
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Read More
- Five stocks we like better than electroCore
- Expert Stock Trading Psychology Tips
- How to Build the Ultimate Everything ETF Portfolio
- The Significance of Brokerage Rankings in Stock Selection
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is the Euro STOXX 50 Index?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.